News
J&J's Tremfya outperforms Novartis' Cosentyx in psoriasis
A large head-to-head study has shown Johnson & Johnson’s psoriasis drug Tremfya outperformed Novartis’ rival, Cosentyx, which had previously set standards in moderate to severe disease.
